Moclobemide Sandoz (Moclobemide)

Moclobemide reversibly inhibits the enzyme monoamine oxidase A, which normally breaks down serotonin, norepinephrine and dopamine. By blocking this enzyme, the drug raises the levels of these neurotransmitters, helping to improve mood and reduce depressive symptoms.

The specific dose of Moclobemide Sandoz is determined by the prescribing clinician based on the individual’s medical condition, response to therapy and tolerability. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for moclobemide in pregnancy and lactation are limited. Healthcare providers usually weigh the potential benefits against possible risks before prescribing it to pregnant or nursing women. Patients should discuss any concerns with their doctor.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moclobemide is a reversible MAO‑A inhibitor, distinguishing it from irreversible MAOIs and from selective serotonin reuptake inhibitors (SSRIs). Its reversible action generally results in fewer dietary restrictions and a lower risk of severe hypertensive reactions compared with classic MAOIs, while offering a different mechanism than SSRIs.

Moclobemide Sandoz should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain stability.

Moclobemide Sandoz is taken orally, usually with or without food, as directed by a healthcare professional. The tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

The most serious risks include hypertensive crisis when high‑tyramine foods are consumed, serotonin syndrome when combined with other serotonergic drugs, severe liver injury, agranulocytosis, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome.

Moclobemide is contraindicated in patients with a known hypersensitivity to the drug, those currently taking other MAO inhibitors, individuals with severe liver disease, and patients who have experienced a hypertensive crisis related to tyramine ingestion. It should also be avoided in patients with certain psychiatric conditions such as uncontrolled mania.